-- 週四下午晚些時候，醫療保健類股上漲，紐約證券交易所醫療保健指數上漲2.6%，道富醫療保健精選行業SPDR ETF (XLV)上漲2.3%。 iShares生物技術ETF (IBB)上漲1.9%。 在公司新聞方面，UniQure (QURE)股價飆升超過16%，此前該公司表示計劃在第三季向英國提交AMT-130的上市許可申請，用於治療亨廷頓氏症。 Axsome Therapeutics (AXSM)股價飆漲12%，此前該公司表示，美國食品藥物管理局(FDA)已批准Auvelity用於治療阿茲海默症失智症相關的躁動症狀。 禮來公司(LLY)上調了全年業績預期，並公佈了超出市場預期的第一季業績，其中Mounjaro的銷售額增長超過一倍。禮來股價上漲超過10%。 美國食品藥物管理局（FDA）提議將替澤帕肽、索瑪魯肽和利拉魯肽從503B原料藥清單中移除，理由是臨床上沒有必要將原料藥外包給其他機構進行配製。禮來公司生產替澤帕肽，其商品名為Mounjaro，用於治療第2型糖尿病，以及Zepbound，用於治療慢性體重管理。諾和諾德公司（Novo Nordisk，股票代號：NVO）生產索瑪魯肽，其商品名為Ozempic，用於治療2型糖尿病，以及Wegovy，用於治療慢性體重管理；利拉魯肽的商品名為Victoza，用於治療2型糖尿病，以及Saxenda，用於治療慢性體重管理。諾和諾德的股價上漲超過5%。
Related Articles
Mining & Metals
Eldorado Gold Q1 Adjusted Net Earnings Attributable to Holders US$188.2M, or $0.95 EPS
$ELD.TO
Research
Research Alert: Lpla Q1: Beats On Eps, Misses On Revenue, As Advisory Shift Improves Margins
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:LPLA delivered Q1 2026 results, with revenues surging 35% to $5.94B (missing estimates by $60M) and adj. EPS of $5.60 beating Street estimates by $0.13. The wealth management transformation accelerated with advisory revenue reaching $2.62B (+55%) and advisory assets growing to $1.39T (+42%), now representing 59.5% of total client assets. We believe LPLA's strategic shift toward fee-based services continues creating a more stable revenue base while improving operating leverage, with total advisory and brokerage assets reaching $2.34T (+30%). Management lowered the upper end of its 2026 core G&A outlook by $20M to $2.16B-$2.19B, including Commonwealth-related expenses. The Commonwealth acquisition remains on track for Q4 2026 completion with asset retention targeting 90% and updated run-rate EBITDA of $410M. With corporate cash of $567M and leverage at 1.86x, we expect LPLA maintains substantial financial flexibility for growth initiatives and plans to resume share repurchases with an estimated $125M in Q2 2026.
$LPLA
Research
Research Alert: Team: Results And Guidance Surpass Expectations As Cloud Growth Accelerates
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:TEAM delivered a strong Q3 beat with non-GAAP EPS of $1.75 exceeding consensus by $0.41, while total revenue of $1.787B grew 32% Y/Y, surpassing expectations by $90M. Cloud revenues of $1.132B accelerated to 29% growth from 26% in Q2, while Data Center sales of $560.7M surged 44% Y/Y, reaccelerating from Q2's 20% growth. RPO growth accelerated again, up 37% Y/Y reaching $3.996B, demonstrating strengthening demand and larger customer commitments driven by its AI-powered System of Work strategy. Despite restructuring charges of $223.8M, non-GAAP operating margin expanded 800 bps Y/Y to 34%, while free cash flow of $561.3M represented a 31% margin, up from Q2's 11%. Management raised FY 26 revenue growth guidance to 24% from 22%, with operating margin guidance improving to 29% from 25.5%. We view the balanced growth across Cloud migration and Data Center expansion as positive, demonstrating TEAM's ability to optimize customer transitions while maintaining strong operational leverage.
$TEAM